Filing Flows

Filing Flows › Companies › Cannapharmarx › Cash flow

Cannapharmarx cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$127K in Q2 2026 · −$173K over twelve months

Operating cash flow−$127K
Free cash flow−$127K

Analysis

In Q2 2026, Cannapharmarx generated −$127K of operating cash flow. That is $319K more than in Q2 2025 (−$446K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$112K; the largest uses were other financing ($643K), operating cash flow ($112K), capital spending ($61K); besides operations, cash came from other investing ($800K); the cash balance fell by $16K.

Operating cash flow was −$127K against net income of −$1.9M. The largest differences: inventory −$632K, receivables −$269K, deferred revenue +$37K.

Free cash flow

Cannapharmarx: free cash flow by quarterCannapharmarx: free cash flow by quarter−$541KQ3 2024−$180KQ4 2024−$601KQ1 2025−$446KQ2 2025−$803KQ3 2025$1.1MQ4 2025−$244KQ1 2026−$127KQ2 2026
Operating cash flow less capital spending.
Cannapharmarx: operating cash flow against capital spendingCannapharmarx: operating cash flow against capital spendingOperating cash flowCapital spending−$541K$0Q3 2024−$180K$0Q4 2024−$601K$0Q1 2025−$446K$0Q2 2025−$803K$0Q3 2025$1.1M$0Q4 2025−$244K$0Q1 2026−$127K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$127K, Capital spending $0.

Capital allocation, year by year

Cannapharmarx: where the cash came from (up) and went (down), by fiscal yearCannapharmarx: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow −$2.4MFY2021: Net borrowing $477KFY2021: Shares issued $826KFY2021: Capital spending −$6KFY2021: Acquisitions −$39K$1.3MFY2021FY2022: Operating cash flow −$1.4MFY2022: Net borrowing $182KFY2022: Shares issued $290KFY2022: Capital spending −$116K$472KFY2022FY2023: Operating cash flow −$2.3MFY2023: Net borrowing $1.6MFY2023: Capital spending −$81K$1.6MFY2023FY2024: Operating cash flow −$1.7MFY2024: Net borrowing −$483KFY2024FY2025: Operating cash flow −$789KFY2025: Capital spending −$6KFY2025
Over these 5 years operating cash flow totalled −$8.6M; the largest uses were operating cash flow ($8.6M) and net borrowing ($483K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$1K
Debtnone
Net cash$1K
Cash runway0 months

Cannapharmarx is burning cash: its operations consume cash, a free cash flow of −$173K a year at the current rate against $1K of cash and investments: a runway of about 0 months before any new financing.

Where the cash came from and went

Cannapharmarx: sources (+) and uses (−) of cash, Q2 2026Cannapharmarx: sources (+) and uses (−) of cash, Q2 2026Other financing$182KOperating cash flow−$127KNot reconciled−$55KCash drawn (+) / kept (−)$78
Cannapharmarx: sources (+) and uses (−) of cash, TTM to Q2 2026Cannapharmarx: sources (+) and uses (−) of cash, TTM to Q2 2026Other investing$800KOther financing−$643KOperating cash flow−$112KCapital spending−$61KCash drawn (+) / kept (−)$16K

From profit to cash

Cannapharmarx: net income to operating cash flow, Q2 2026Cannapharmarx: net income to operating cash flow, Q2 2026Net income−$1.9MReceivables−$269KInventory−$632KDeferred revenue$37KOperating cash flow−$127K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 20261288679-579
Q4 20252501381093-705
Q3 20254980464-335
Q2 202574106562-381
Q1 202536105529-389
Q4 20241847291-226

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026−$127K—$78−$127K
Q1 2026−$244K—$1K−$244K
Q4 2025$1.1M—−$1K$1.1M
Q3 2025−$803K$787K$16K−$803K
Q2 2025−$446K$462K−$16K−$446K
Q1 2025−$601K$964K$1K−$601K
Q4 2024−$180K$361K$5K−$180K
Q3 2024−$541K—$2K−$541K

Cannapharmarx: income statement and cash flow

Cannapharmarx, Q2 2026: revenue $276K (+19% year over year), operating margin -137.1%. The chart follows the revenue to costs, profit and cash.

Cannapharmarx: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.